3 Biotechs Aim For Combined $300M In Follow-Ons
Xencor Inc., a California biotech developing antibodies to treat autoimmune and allergic diseases and cancer, set terms Wednesday for a follow-on offering that could raise $124.7 million, marking three life sciences...To view the full article, register now.
Already a subscriber? Click here to view full article